Moderna Inc (MRNA)
$147.19 6.18 (4.38%)
11:27 EST MRNA Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 28.37M
Day's Range 128.10 - 149.80
52-Week Range 17.68 - 178.50
Dividend & Yield N/A (N/A)
MRNA Stock Predictions, Articles, and Moderna Inc News
- From InvestorPlace
- From the Web
These short-term stocks are likely to deliver decent returns through the end of 2020. In addition, these stocks are long-term value creators.
Apple, General Motors, Nikola, Moderna and the S&P 500 ETF were our top stock trades for Tuesday. Now, let's look at the charts.
These healthcare stocks can deliver steady growth in the coming decade as demographics suggest tailwinds for the industry.
Buying stocks that have been hit by a serious but solvable problem, can lead to extraordinary gains when things work out positively.
Moderna is up big on the announcment that its Covid-19 vaccine is 95% effective. Now is the time to take your profits in MRNA stock.
With a new Covid vaccine update today, how do the Moderna and Pfizer coronavirus vaccines compare? Dive in here.
MRNA stock is off to a great start Monday thanks to news its coronavirus vaccine candidate is almost 95% effective.
We’re heading into the seasonally strong time of year, and as Thanksgiving week approaches, it is likely the market will take off. So, if you have any cash to invest, please be invested before Thanksgiving!
There are periods when a handful of holdings can become overvalued stocks to sell. Here are seven potential names to watch.
News from Moderna regarding an excellent update from its novel coronavirus vaccine trial has MRNA stock rising on Thursday morning.
As we near the end of 2020, it’s time to safeguard your portfolio before we enter the new year. Here are the top stocks to buy in November.
By Joel Baglole
The U.S. government has pulled out all the stops to develop a treatment for Covid-19. These biotech stocks are leading the race for a cure.
If you’re interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip.
Moderna is looking to get its vaccine emergency use approval. Moderna stock is worth at least one-third more from its Covid-19 vaccine.
By Ian Cooper
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
Navellier RatingsPowered by Portfolio Grader